Pinetree Therapeutics
PrivateLast Round
Series B
Oct 28, 2025
Est. Valuation
$135M
Total Funding Raised
$87.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pinetree Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in October 2025.
Pinetree Therapeutics is a biotechnology company developing transformative therapies through targeted protein degradation for oncology and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pinetree Therapeutics Comparables
Compare Pinetree Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EpiBiologics | 85% | |
| Lycia Therapeutics | 84% | |
| Avilar Therapeutics | 79% |
For institutional investors. Book with your work email.
Pinetree Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 28, 2025 | ||||
| Series A Extension | Jul 30, 2024 | ||||
| Series A | Jun 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pinetree Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series A |
| SV Investment | Series B |
| DSC Investment | Series B, Series A, Series A Extension |
| Smilegate Investment | Series B |
| STIC Investments | Series A Extension |
| Korea Investment Partners | Series B |
| S&S Investment | Series B, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
EGFR AbReptorTM licensed to AstraZeneca for development.
- Jul 26, 2026
Monthly visitors increased 65% MoM, reaching 2.9K.
For institutional investors. Book with your work email.
Pinetree Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pinetree Therapeutics's valuation, stock price, and market status.
Is Pinetree Therapeutics a public or private company?
Pinetree Therapeutics is a private company.
What is the current stock price of Pinetree Therapeutics?
Pinetree Therapeutics is a private company, so its shares have no public market price. Caplight tracks Pinetree Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pinetree Therapeutics worth (valuation)?
Pinetree Therapeutics's valuation is estimated at $135.0M based on funding round data.
Can I buy Pinetree Therapeutics stock?
Pinetree Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pinetree Therapeutics's last funding round?
Pinetree Therapeutics's most recent funding round was Series B on October 28, 2025.
Who are the main investors in Pinetree Therapeutics?
Key investors in Pinetree Therapeutics include DSC Investment, STIC Investments.
Will Pinetree Therapeutics IPO soon?
No public IPO plans have been announced for Pinetree Therapeutics.
How can I track Pinetree Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Pinetree Therapeutics's shares on secondary markets.